Placeholder Banner

BIO Submits Comments to EMA on Strategies to Identify and Mitigate Risks for First-In-Human and Early Clinical Trials with Investigational Medicinal Products

February 28, 2017

BIO submitted comments to the European Medicines Agency (EMA) on the guideline, Strategies to Identify and Mitigate Risks for First-In-Human and Early Clinical Trials with Investigational Medicinal Products.

BIO says it’s important the guideline acknowledges and differentiates the requirements for trials conducted in high-morbidity and high-mortality disease states such as advanced stage cancers, as in such settings more flexibility should be applied. This is already recognized by regulators in other guidance documents (e.g., ICH S9 guideline). Other comments include discussion of maximum doses in healthy volunteer studies, sentinel dosing, and more.

Download Full Comments Below
2017.02.28 BIO Comments On EMA First-in-human FINAL
Click the link below for full comments
Discover More
The undersigned food, agriculture, and seafood trade associations respectfully urge the expeditious nomination of the Chief Agricultural Negotiator at the Office of the U.S. Trade Representative. America’s farmers, ranchers, processors, exporters…
The undersigned trade associations and private sector organizations write to express our strong support for the Endless Frontier Act, sponsored by Senate Majority Chuck Schumer (D-NY) and Senator Todd Young (R-IN), which would provide much needed,…
Dr. Michelle McMurry-Heath, along with a group of business and policy leaders, sends an open letter to President Biden urging him "to demonstrate decisive U.S. leadership" to combat COVID-19 in Latin America, Europe, Asia, and Africa…